Form 4: Avadel Pharmaceuticals Executive Granted Stock Options

Richard J. Kim, Chief Commercial Officer of Avadel Pharmaceuticals, received stock options for 147,000 ADSs on February 20, 2024.

Summary

• Richard J. Kim, the Chief Commercial Officer of Avadel Pharmaceuticals PLC, was granted stock options on February 20, 2024.
• The options are for 147,000 American Depositary Shares (ADSs).
• The exercise price of the options is $13.57.
• The options vest in four equal installments of 36,750 ADSs on each of the first four anniversaries of the grant date.
• The options expire on February 20, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting confidence in the company's future performance. The sentiment is neutral to positive.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the executive to remain with the company for the long term.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Teva Pharmaceutical Industries and Mylan (now Viatris) also utilize stock options as part of their executive compensation plans.
• The vesting schedule of four years is typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning executive interests with company performance.
• Employees may see this as a sign of stability and potential growth within the company.

Key Dates